Intelligence · Clinical Pipeline
HOFFMANN-LA ROCHE Pipeline
All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.
- Programs
- 58
Quick answer
HOFFMANN-LA ROCHE has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
RO5503781 MBP
Hoffmann-La Roche
Myelogenous Leukemia, Acute
1 trial -
RO7119929
Hoffmann-La Roche
Carcinoma, Hepatocellular
1 trial -
RO7507062
Hoffmann-La Roche
Systemic Lupus Erythematosus
1 trial -
Rugonersen
Hoffmann-La Roche
Angelman Syndrome (AS)
1 trial -
Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE
Hoffmann-La Roche
Urothelial carcinoma (UC)
1 trial -
Trastuzumab
Hoffmann-La Roche
Early Breast Cancer
1 trial -
atorvastatin
Hoffmann-La Roche
Healthy Volunteer
1 trial -
balapiravir [RO4588161]
Hoffmann-La Roche
Dengue
1 trial -
danoprevir
Hoffmann-La Roche
Healthy Volunteer
1 trial -
trastuzumab [Herceptin]
Hoffmann-La Roche
Healthy Volunteer
1 trial
Frequently asked questions
How many pipeline programs does HOFFMANN-LA ROCHE have?
58 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs